Under the agreement, N-of-One will analyze molecular profiles and mutations identified through genome sequencing and deliver treatment strategy profiles to Fox Chase physicians who have ordered the CancerCode-45 sequencing for a patient.
“We are the link between the sequencing being done and the point of care,” said Chris Cournoyer, CEO of N-of-One.
The treatment strategy profiles interpret and inform the findings from the test. According to Jennifer Levin Carter, MD, founder and CMO of N-of-One, after interpreting the molecular profiles, N-of-One comes up with additional treatment options 95 percent of the time, and 40 percent of treating physicians change their treatment strategy after receiving the interpretation.
More Articles on Cancer Centers:
City Hospital in West Virginia Opens Cancer Center
Moffitt Cancer Center to Break Ground on $74.1M Outpatient Facility
Stanford Hospital & Clinics to Open Outpatient Cancer Center
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
